Search

everythinglearnresearchcommunity

for

Search:↓

The conclusion is that individual differences in COVID-19 severity are influenced by factors like age, sex, race, and genetics, which are important for personalized medicine.

Early genetic testing and JAK inhibitors can help treat systemic inflammation in SAVI patients.

Patient-derived melanocytes can potentially treat vitiligo by restoring skin pigmentation.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

About a quarter of the participants experienced hair loss after COVID-19 vaccination.

Finasteride increases hair density in female androgenetic alopecia, but individual results may vary.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

Some patients treated with peginterferon and ribavirin for chronic hepatitis C had mild to moderate skin reactions, but treatment did not need to be stopped.

Cell aging can be both good and bad for tissue repair.

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.

Trichloroethylene causes skin inflammation in mice by increasing certain immune proteins.

Antidepressants might help with skin inflammation and improve conditions like psoriasis and eczema.

Latanoprost therapy potentially caused a woman's white hair to darken again.

New treatments for Alopecia Areata show promise but need to be more effective and affordable.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Many research paper titles in dermatology journals lack scientific precision.

A girl developed vitiligo and psoriasis after hepatitis B treatment, and stopping the treatment didn't help.

A woman developed white patches on her skin and curly hair after hepatitis C treatment, likely due to the medication interferon alpha.

Vogt-Koyanagi-Harada disease can develop during interferon therapy for chronic hepatitis C.

Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.

A patient developed a blister at the injection site after hepatitis C treatment.

A woman's total hair loss from hepatitis C treatment grew back after stopping the medication.

Interferon β from hair cells stops the growth of other hair cells.

A man lost all his hair permanently after hepatitis C treatment, a side effect not seen before.

Certain medications can cause serious side effects, so it's important to report them.

Type I interferons play a key role in the development of various skin diseases.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Dengue virus can infect human hair follicle cells and may cause hair loss.